



SIDNEY ALAN FUNK, M.D.

RADIANT RESEARCH, ATLANTA

1100 Lake Hearn Drive, Suite 360
Atlanta, Georgia 30342

PRIVATE PRACTICE

980 Johnson Ferry Rd., Suite 720
Atlanta, Georgia 30342

Phone (404) 255-6005
Fax (404) 255-2888

EDUCATION

1962 - 1966 MD Medical College of Georgia, Augusta, GA
1958 - 1962 BA Emory University, Atlanta, GA

TRAINING

1966 - 1967 Internship: Kings County Hospital, Brooklyn, NY
1969 - 1972 Residency: Obstetrics and Gynecology, Bronx Municipal Hospital, Bronx, NY
1973 - 1973 Chief Resident: Obstetrics & Gynecology, Albert Einstein College of Medicine, Bronx, NY

Military
1967-1969 Experience: San Diego United States Naval Hospital, Vietnam - USS Colleton

MEDICAL EXPERIENCE

1995 - Present Medical Director, Principal Investigator - Radiant Research, Atlanta, GA
1981 - Present Private Practice, Gynecology, Sidney A. Funk, M.D., P.C., Atlanta, GA
1995 - 1995 Medical Director, Principal Investigator - Future HealthCare Research Center, Atlanta, GA
1973 - 1981 Private Practice, Obstetrics and Gynecology, North Atlanta OB/GYN, Atlanta, GA
1973 - 1973 Assistant Instructor, Obstetrics and Gynecology, Albert Einstein College of Medicine
Bronx, NY

CERTIFICATION AND LICENSURE

Licensure: State of Georgia #011333
Certification: Diplomate, American Board of Obstetrics and Gynecology

CLINICAL RESEARCH EXPERIENCE

1. Phase III Comparative Randomized Study of XXX and XXX Oral Contraceptive.
2. Pilot Study of the Cellular and Histological Endometrial Effects of Continuous XXX in Combination with Different Doses of Continuous Cyclic XXX in Postmenopausal Women, and Addendum 1 - The Population Pharmacokinetics of Unconjugated and Total XXX and XXX, XXX, XXX and XXX in Postmenopausal Women.
3. An Open-Label, Randomized, Parallel Group Comparative, Multicenter, Safety and Efficacy Study of Combination XXX Oral Contraceptives, XXX and XXX Versus XXX.
4. An Open-Label, Noncomparative Efficacy and Safety Study of XXX, a One-Rod Contraceptive Implant Containing 3-Ketodesogestrel in Healthy Female Volunteers, with Subsets for Pharmacokinetic Measurements, Ophthalmological Assessments, Carbohydrate Metabolism, Lipid Metabolism and Endometrial Morphology.

5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of XXX in the Treatment of Osteoporosis in Elderly Women.
6. An Open-Label, Multicenter Non-Comparative Safety and Efficacy of the Desogestrel Containing Oral Contraceptive XXX.
7. A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 5-FU/epi Gel Manufactured at Two Different Sites When Administered to Patients with External Condylomata Acuminata Lesions Measuring 55 mm or Less.
8. A Randomized Double-Blind Study Comparing Efficacy and Safety of a Continuous Low Dose of XXX Versus Placebo Released from a Vaginal Ring in the Treatment of Persistent Signs and Symptoms of Vaginal Atrophy in Postmenopausal Women on Oral Systemic Estrogen Replacement Therapy, Followed by a Non-Controlled One-Year Extension.
9. Efficacy of XXX Vaginal Ovule (3 Day Treatment) Versus XXX Vaginal Cream (7 Day Treatment) in Bacterial Vaginosis.
10. XXX 10ug, XXX 25 ug, and Placebo - A Randomized, Double-Blind, Controlled, Parallel Study of Efficacy and Safety in Patients with Estrogen Deficiency Derived Atrophic Vaginitis.
11. A Double-Blind, Randomized, Parallel-Group, Multicenter, Dose-Finding Study Comparing the Efficacy and Safety of 1mg 17B - Estradiol XXX in Combination with Low Doses of XXX with that of 1mg 17B - Estradiol Alone on the Endometrium In Postmenopausal Women.
12. Assessment of Bone Mineral Density in Women Receiving XXX, a Contraceptive Injection.
13. An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of XXX Inhalation Therapy for the Management of Endometriosis.
14. A Double-Blind Multicenter Study Comparing the Efficacy and Safety of Two Doses of an Estradiol Matrix Transdermal Delivery System (EMTDS) with Two Doses of Conjugated Estrogen Therapy in the Treatment of Women with Postmenopausal Symptoms.
15. An Open-Label Multicenter Study Evaluating Safety and Efficacy of XXX 25ug During Long Term Treatment of Estrogen Deficiency Derived Atrophic Vaginitis.
16. A Randomized, Double-Blind, Parallel Group Study Comparing the Absorption of 17-B Estradiol During Treatment with XXX 10ug and 25ug.
17. A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Menopausal Symptom Study of Three Doses of RPR XXX/XXX Acetate (NETA) Patches in a Sequential Wear Hormone Replacement Therapy (HRT) Regimen.
18. A Double-Blind, Randomized Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of XXX Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections.
19. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of XXX in the Prevention and/or Progression of Influenza A and B Viral Infections.

20. A Randomized, Double-Blind, Placebo-Controlled, Parallel, Multicenter Study to Assess the Efficacy and Safety of Three Strengths of a 7-Day XXX Transdermal System for Relief of Menopausal Vasomotor Symptoms (with an Open-Label XXX Arm).
21. A Randomized, Open Label, Parallel Group Study to Evaluate Three Doses of a Transdermal Contraceptive System of XXX and XXX with Regard to Ovulation, Cycle Control, and Safety vs. XXX Tablets or XXX Tablets in Healthy Ovulating Female Volunteers.
22. A North American Multicenter Randomized Evaluation of XXX Complex (XXX) Capsules for Fibrocystic Disorder (FCD) of the Breast.
23. XXX-XXX Contraceptive Injection: A Comparative Study of Safety, Patient Acceptability and Efficacy to XXX, 28 Tablets.
24. A Randomized, Double-Blind, Active-Controlled, Parallel, Multicenter Study to Assess the Efficacy and Safety of Three 1/2-Day Combinations of XXX/XXX Acetate Transdermal Delivery Systems for Relief of Menopausal Vasomotor Symptoms and Reduction of Endometrial Hyperplasia.
25. A Multicenter, Prospective, Randomized, Single-Blind, Parallel-Group Comparison of the Safety and Efficacy of the XXX 1-Day Regimen (500 mg Vaginal Insert) with the XXX 7-Day Regimen (100 mg Vaginal Insert) in the Treatment of Vulvovaginal Candidiasis.
26. A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of XXX for the Treatment of Dysfunctional Uterine Bleeding.
27. A Comparison of Two Oral Contraceptives: XXX vs. XXX 1/20.
28. A Randomized, Double-Blind, Placebo-Controlled, Parallel, Multicenter Study to Assess the Efficacy and Safety of Three Strengths of a 7-Day XXX XXX System for Relief of Menopausal Vasomotor Symptoms (with an Open Label XXX ARM).
29. A Multicenter, Prospective, Randomized, Single-Blind, Parallel-Group Comparison of the Safety and Efficacy of the XXX 1-Day Regimen (500 mg Vaginal Insert) with the XXX 7-Day Regimen (100 mg Vaginal Insert) in the Treatment of Vulvovaginal Candidiasis.
30. A Randomized Double-Blind, Placebo Controlled, Efficacy and Safety Study of Oral XXX in Patients with Recurrent Genital Herpes.
31. A Randomized, Double-Blind, Placebo Controlled, Efficacy and Safety Study of Oral XXX in Patients with Recurrent Herpes Labialis.
32. A Multicenter, Double-Blind, Placebo-Controlled Randomized Study to Determine Efficacy in the Relief of Hot Flashes in Women Receiving Transdermal XXX.
33. A Double-Blind, Randomized, Placebo Controlled Trial Three Doses of XXX and XXX for the Prevention of Postmenopausal Osteoporosis.
34. A Double-Blind, Randomized, Multicenter, Placebo Controlled Trial of 1.25 and 0.5 mg of XXX for the Treatment of Postmenopausal Osteoporosis.

35. A Multicenter, Double-Blind, Randomized Comparison of Continuous Oral XXX-XXX Combination and Continuous Oral XXX, Examining the Effect on the Endometrium, Symptoms and Bleeding Patterns in Postmenopausal Women.
36. A Multicenter, Double-Blind, Placebo-Controlled Randomized Study to Determine Efficacy in the Relief of Hot Flushes in Women Receiving Transdermal XXX.
37. Dose Range Finding and Efficacy Study of XXX in Women with Heavy Bleeding Secondary to Uterine Leiomyomata.
38. A Randomized Double-Blind, Placebo Controlled Study of Craving and Withdrawal Symptom Alleviation During XXX Tapering.
39. An Open-Label, Non-Comparative, Multicenter Study to Evaluate Contraceptive Efficacy, Cycle Control and Safety of a One-Compartment XXX Vaginal Ring.
40. A Multicenter, Dose-Finding Study Comparing the Efficacy of XXX, a Once-A-Week XXX-XXX Combination Transdermal System (TDS), with Placebo in the Treatment of Vasomotor Symptoms Associated with Menopause.
41. A Randomized, Double-Blind, Multicenter, Comparative Trial of 1 mg XXX-XXX in Combination with 0.25 mg or 0.5 mg XXX-XXX and XXX.
42. A 12-Week, Randomized, Parallel Group, Multicenter, Wear Study to Assess Skin Tolerability with a 40-Week Safety Extension Period Comparing Three Continuous Doses Regimens (0.1, 0.2 and 0.4 mg/Day XXX Combined with 0.05 mg/Day XXX) under Conditions of Routine Clinical Use.
43. Genital Herpes Oral Suppression Trial (GHOST) of Oral XXX. A Randomized, Double-Blind, Placebo-Controlled Trial.
44. An Evaluation of the Clinical Performance Characteristics of the XXX IV Safety Catheter in Human Volunteers.
45. A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneously Administered XXX to Obese Patients.
46. 2% Vaginal Cream – A Clinical Efficacy Study of Bioequivalence of Two Problems.
47. A Dose-Range Study to Evaluate XXX, Placebo and XXX when Administered to Female Subjects with Unstable Bladder Conditions.
48. A Double-Blind, Randomized, Multicenter, Parallel Group Study Comparing the Therapeutic Equivalence and Safety of XXX Vaginal Cream with XXX in the Treatment of Vulvovaginal Candidiasis.
49. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of XXX with Dysmenorrhea.
50. A Multicenter, Double-Blind, Placebo-Controlled Evaluation of XXX for the Prevention/Blockage of the Progression of Cold Sore Lesion Development (Mouth Area).

51. A Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Effects of Two Hormone Replacement Regimens, XXX and XXX on Triglyceride Levels in Postmenopausal Women with Mild to Moderate Hypertriglyceridemia.
52. A Long-Term, Open-Label, Safety and Tolerability Study of XXX in Addition to XXX in Subjects with Primary Hypercholesterolemia who have Previously Completed the 12-Week Double-Blind Study.
53. Prospective, Randomized, Double-Blind Study Comparing XXX XXX 300 mg PO BID for Five Days with XXX/XXX 160/800 mg PO BID for Five Days in the Treatment of Patients with Acute, Uncomplicated Lower Urinary Tract Infections.
54. A Randomized, Double-Blind, Dose-Ranging, Parallel-Group Study to Compare the Safety and Efficacy of XXX 10-XXX XXX XXX (XXX) (0.3, 0.625, and 1.25 mg modified release) with Placebo in Postmenopausal Women Suffering From Moderate to Severe Vasomotor Symptoms.
55. A Study of Bleeding Pattern in Pre-Menopausal Women after Subcutaneous Administration of 20 mg XXX in Combination with Either 2.5, 5.0, 7.5 or 10.0 mg XXX.
56. Multi-Center Efficacy Study Comparing XXX XXX XXX, A Once a Week XXX-XXX Combination Transdermal System (15cm² 1%XXX/1% XXX TDS, 15cm² 1% XXX/0.35% XXX TDS), with Placebo in Treatment of Vasomotor Symptoms Associated with Menopause.
57. A Multi-Center, Double-Blind, Randomized Comparison of Continuous Oral XXX XXX Combinations and Continuous Oral XXX, Examining the Effect on the Endometrium, Symptoms, and Bleeding Patterns in Postmenopausal Women.
58. A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneously Administered XXX in Obese Subjects.
59. A Phase II, Randomized, Double-Blind, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of XXX in Patients with Uterine Leiomyomata.
60. Phase III Contraception Study of XXX XXX XXX Subcutaneous Injection (XXX-XXX) in Women of Childbearing Potential in the Americas (Including Bone Mineral Density [BMD] Sub-Study Comparing the Effects of XXX-XXX and XXX-XX)
61. Phase III Study of XXX XXX XXX Subcutaneous Injection (XXX-XXX) in Women with Endometriosis in U.S. and Canada.
62. A Multicenter, Randomized, Double Blind, Placebo-Controlled, Safety and Efficacy Study of XXX in Women with Dysmenorrhea.
63. A Randomized, Double-Blind, Placebo-Controlled Evaluation of XXX for the Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples.
64. A Randomized, Open-Label, Comparative, Multi-Center Trial to Evaluate Contraceptive Efficacy, Cycle Control, Safety and Acceptability of a Monophasic XXX Containing 200 ug XXX XXX and 20 ug XXX, Compared to a XXX containing 100 ug XXX and 20 ug XXX.
65. A Multicenter, Double-Blind, Placebo-Controlled Evaluation of XXX for the Prevention/Blockage of the Progression of Cold Sore Lesion Development.

66. A Randomized, Double-Blind, Parallel, Multicenter Study to Evaluate the Effects on Cycle Control of Three XXX/XXX XXX Regimens Versus an Open-Label XXX Treatment Arm.
67. A Double-Blind, Randomized, Multicenter, Parallel Group study Comparing the Therapeutic Equivalence and Safety of XXX XXX 4% Vaginal Cream (XXX) with XXX-XXX Vaginal Cream (XXX XXX) in the Treatment of Vulvovaginal Candidiasis.
68. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of XXX in Women with Dysmenorrhea.
69. A Dose-Range Study to Evaluate (X)-XXX, Placebo and XXX XXX When Administered to Female Subjects with Unstable Bladder Conditions. A Randomized, Double-Blind XXX and XXX Controlled Study of XXX in Subjects with Mild to Moderate Hypertension
70. XXX Contraceptive Injection: An Open-Label Continuation Protocol for Patients Successfully Completing XXX or XXX.
71. A Double-Blind, Placebo-Controlled, Fixed-Dosage Study to Assess the Efficacy and Tolerability of XXX CR in the Treatment of Hot Flashes Associated with Menopause
72. A Study of the Safety and Efficacy of XXX for the Prevention of Bone Loss and for Lipid Lowering in Postmenopausal Women at Risk for Osteoporosis.
73. A Study of the Safety and Efficacy of XXX for the Prevention of Bone Loss and for Lipid Lowering in Postmenopausal Women at Risk for Osteoporosis.
74. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, 12-Week Study Assessing the Effects of XXX on Vasomotor Symptoms in Postmenopausal Women of Minority Ethnic Groups.
75. A Randomized, Double-Blind, 36-Week Trial Comparing Impact of Breakthrough Bleeding in Postmenopausal Women on XXX and XXX in a Managed Care Setting.
76. A Study of the Safety and Efficacy of XXX in the Treatment of Vaginal Atrophy in Postmenopausal Women.
77. A Double-Blind Placebo-Controlled, Parallel Group Design Study of Two Doses of XXX vs. Placebo for the Treatment of Sexual Dysfunction (Arousal Disorder) in Postmenopausal Women.
78. A Double-Blind Placebo-Controlled, Parallel Group Design Study of Two Doses of XXX vs. Placebo for the Treatment of Sexual Dysfunction (Hypoactive Desire) in Postmenopausal Women.
79. A Phase II, Randomized, Double-Blind Parallel Group Pilot Study to Evaluate the Safety and Efficacy of XXX in Patients with Uterine Leiomyomata.
80. Phase III Contraception Study of XXX Subcutaneous Injection (XXX) in Women of Childbearing Potential in the Americas (Including a Bone Mineral Density [BMD] Sub-Study Comparing the Effects of XXX and XXX). Also Including a Return of Ovulation Sub-Study.
81. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of XXX in Women with Dysmenorrhea.

Funk, M.D.

82. Double-Blind, Placebo and Active Controlled Study of Sustained Release XXX in Subjects with Symptoms of Overactive Bladder of Urgency, Frequency and Urinary Incontinence.
83. Open-Label Extension Study of Sustained Release XXX in Subjects with Symptoms of Overactive Bladder.
84. A Randomized, Double-Blind, Placebo-Controlled Evaluation of XXX for the Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples.
85. A Randomized, Open-Label, Comparative, Multicenter Trial to Evaluate Contraceptive Efficacy, Cycle-Control, Safety and Acceptability of a Monophasic COC Containing 200u XXX and 20u XXX Compared to a COC Containing 100u XXX and 20u XXX
86. A Phase III, Vehicle-Controlled Study of Topical XXX (XXX) 0.01% Gel Applied 2 times Per Week for 3 Weeks for Each Recurrence of Herpes Genitalis Over 12 Months.
87. A Phase III, 12-Month, Double Blind, Randomized, Parallel Group, Placebo Controlled, Efficacy and Safety Study of XXX in Overweight and Obese Subjects With a 12-Month Open-Label Extension Phase.
88. XXX XXX Herpes Simplex Antibody Test Clinical Trial Part 2.
89. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing an prevention of Weight Regain Effects and Safety of XXX in Obese Patients with or without Comorbidities.
90. A Phase 3, Multicenter, Open-Label Study To Evaluate The Safety And Efficacy Of XXX 90 MCG And XXX 20 MCG In A Continuous Daily Regimen For Oral Contraception.
91. A Double-Blind, Placebo-Controlled, Parallel Group Design Dose-Ranging Study of Three Doses of XXX vs. Placebo for the Treatment of Sexual Dysfunction (Arousal Disorder) in Postmenopausal Women.
92. A Double-Blind, Placebo-Controlled, Parallel Group Design Dose-Ranging Study of Three Doses of XXX vs. Placebo for the Treatment of Sexual Dysfunction (Hypoactive Disorder) in Postmenopausal Women.
93. A Phase III, Multi-Center, 6-Month, Randomized, Double-Blind Study to Evaluate the Safety of Two Doses of XXX in Subjects with Uterine Leiomyomata.
94. A Placebo-Controlled Study Evaluating the Safety and Efficacy of XXX 3mg and 5mg in Women with Overactive Bladder.
95. A Phase3, 12-Month, Extension Study to Evaluate the Safety of XXX in Subjects with Uterine Leiomyomata.
96. A Phase III, Randomized, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of Combination Oral Contraceptive Regimens Utilizing XXX During the Pill-Free Interval for Prevention of Pregnancy in Women.
97. An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of XXX 1g Once Daily vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Infected Immunocompetent Subjects.
98. A Multi-Center, Randomized, Parallel-Group, Investigator-Blinded Study to Compare the Safety and Efficacy of XXX® 1 Combination Pack in Bedtime versus Daytime Administration.
99. The Safety and Efficacy of a Combination of XXX and YYY in Patients with Dyslipidemia: A Dose-Ranging Study.

100. Efficacy and Safety of XXX compared With Placebo, Pelvic Floor Muscle Training, and Combined XXX/Pelvic Floor Muscle Training in Subjects with Moderate to Severe Stress Urinary Incontinence.
101. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Fixed Dose, Multi-Center Study to Evaluate the Efficacy, Safety and Toleration of Oral XXX Administered for 12 Weeks to Premenopausal Women Who Have Been Diagnosed With Female Sexual Arousal Disorder.
102. An Open-Label, Multi-Center Extension Study to Evaluate the Safety, Toleration and Sustained Efficacy of Oral XXX Administered to Women Who Have Been Diagnosed with Female Sexual Arousal Disorder.
103. A Multi-National, Multi-Center, Randomized, Double-Blind, Parallel Group, Active Controlled, comparative Trial, To Assess the Endometrial Histological Profile Following Treatment With XXX Versus Conjugated Estrogen Plus Medroxyprogesterone Acetate in Postmenopausal Women.
104. A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose, Multi-Center Study to Evaluate the Efficacy, Safety and Toleration of Oral XXX Administered For 12 Weeks to Post-Menopausal Women Who Have Been Diagnosed With Female Sexual Arousal Disorder.
105. Double-Blind, Placebo-Controlled, Parallel Group Design Study of Two Doses of XXX vs. Placebo for the Treatment of Sexual Dysfunction (Arousal Disorder) in Postmenopausal Women.
106. Double-Blind, Placebo-Controlled, Parallel Group Design Study of Two Doses of XXX vs. Placebo for the Treatment of Sexual Dysfunction (Arousal Disorder) in Postmenopausal Women.
107. A Double-Blind, Placebo-Controlled, Parallel Group Design Study of Two Doses of XXX vs. Placebo for the Treatment of Sexual Dysfunction (Hypoactive Disorder) in Postmenopausal Women.
108. A Double-Blind, Placebo-Controlled, Parallel Group Design Dose-Ranging Study of Three Doses of XXX vs Placebo for the Treatment of Sexual Dysfunction (Hypoactive Disorder) in Postmenopausal Women.
109. A Twelve Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-Up Evaluating the Safety and Efficacy of XXX in Comparison to YYY® For Smoking Cessation.
110. A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of XXX for the Relief of Vasomotor Symptoms Associated with Menopause.
111. A Phase 3, Multicenter Study to Evaluate the Return to Spontaneous Menses for Subjects Receiving Prior Treatment With a Continuous Daily Regimen of XXX and YYY for Oral Contraception.
112. A Phase 3, Multicenter, Open-Label, Study to Evaluate the Safety and Efficacy of XXX 90 MCG and YYY 20 UG in a Continuous Daily Regimen for Oral Contraception.
113. A Multicenter, Double-Blind, Placebo-Controlled comparison of Multiple Doses of XXX and XXX, in combination and alone, in relieving vasomotor symptoms in postmenopausal women.